Unveiling the Complexities of Metastatic Breast Cancer: A Journey into Biomarker Diversity
In the world of cancer research, a fascinating yet challenging aspect is the study of metastatic breast cancer, particularly invasive lobular carcinoma (ILC). Recent studies have shed light on the remarkable diversity within this cancer type, raising important questions about our current treatment approaches.
Biomarker Differences: A Tale of Intra-Patient Variability
Researchers delved into the intricate world of metastatic ILC, examining key biomarkers such as stromal tumour-infiltrating lymphocytes (sTIL), oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and KI67. Through two postmortem tissue donation programs, UPTIDER and Hope for Others, they uncovered a surprising level of heterogeneity.
The study analyzed 306 metastases from 12 patients, revealing low sTIL levels in both primary tumors and metastases. Median values ranged from 0.67% to 6.67%, indicating a significant variation. Regression modeling further highlighted the differences, with metastases showing significantly lower ER and PR expression and higher KI67 expression compared to primary tumors. Interestingly, HER2 low metastases were identified in most patients, but the proportion varied widely.
The Discrepancy Between Imaging and Pathology
A central review of radiology and pathology revealed a moderate concordance in detecting metastatic ILC. The median concordance at the organ level was 78%, and at the patient level, it was 71%. These findings suggest a potential mismatch between imaging and pathological assessments, which could impact disease monitoring.
Implications for Treatment Selection: A Call for Comprehensive Strategies
The data suggest that relying on a single metastatic biopsy may not capture the full biological complexity of metastatic ILC. Given the observed heterogeneity in hormone receptor expression, proliferation index, and HER2 status, a more holistic approach is needed. Clinicians managing these patients must consider the variability of the tumor when planning therapeutic strategies.
But here's where it gets controversial... Should we be reevaluating our current treatment protocols? Are there more effective ways to detect and monitor metastases? And this is the part most people miss: the importance of postmortem tissue donation programs in advancing our understanding of cancer.
What are your thoughts on this? Do you think our current treatment approaches need an overhaul? Share your insights in the comments below!
